Event Information

Recently, a bill introduced by a bipartisan group of Select Committee Members in the Senate and the House could severely impact U.S. companies' ability and desire to contract with biotechnology entities from China, Russia, Iran, and North Korea.


The bill, called the "BIOSECURE Act" ("the Act"), would prohibit executive agencies from contracting with or extending loans or grants to any company with current or future commercial arrangements with a "biotechnology company of concern." Generally speaking, a "biotechnology company of concern" is a biotechnology company that is headquartered in or subject to the jurisdiction of a foreign adversary's government and poses a threat to national security. The bill also specifically names certain companies related to the People's Republic of China ("PRC")—BGI, MGI, Complete Genomics, WuXi Apptec, and their affiliates—as companies of concern.


What implications does the BIOSECURE Act and the U.S.-China rivalry hold for the future of biotechnology innovation in China? How might the BIOSECURE Act and the U.S. - China tech rivalry impact market and investment strategies within the biotechnology sector? As the U.S.-China tech rivalry escalates in biotechnology, what should multinational companies anticipate? What steps can multinational companies in China take to prepare themselves in response to the BIOSECURE Act and the U.S.- China rivalry in biotechnology?


On April 26, AmCham Legal Affairs Committee and Healthcare Committee will invite the industry experts to interpret the BIOSECURE Act, the main topics will be:

  • Comprehensive overview of the BIOSECURE Act, encompassing its scope, prohibitions, and key definitions, while delving into the Act's background and its primary objectives.
  • Analysis of the potential ramifications for life science and biotechnology companies should the Act be adopted.
  • Examine the latest amendments to the Act and evaluate their potential implications.
  • Share our view regarding the potential legislative trajectory for the Act in Congress.


Event details:

  • Event format: AmCham Office
  • Time & Date: 9:00 - 12:00, Thursday, May 9 ( Registration will start from 9:00pm)
  • Language: Chinese
  • Contact: Edward Wang, xwang@amchamchina.org; Ada Yang, ayang@amchamchina.org


Notes:

  • Registration is required to access the meeting. Registration and refund close at 5:00 PM (China time),May 8.
  • Please make sure to register with your company email address.
  • Registration at the door is not accepted.


近期,美国参议院和众议院两党特别委员会成员小组提出的一项法案可能会严重影响美国公司与中国、俄罗斯、伊朗和朝鲜的生物技术实体签订合同的能力和愿望。


该法案被称为"生物安全法案"("该法案"),将禁止行政机构与任何与"关注的生物技术公司"有当前或未来商业安排的公司签订合同或向其提供贷款或赠款。一般来说,"关注的生技技术公司"是指总部位于外国对手政府或受其管辖并对国家安全构成威胁的生物技术企业。该法案还特别将某些与中华人民共和国("PRC")相关的公司——华大基因、MGI、全基因组、药明康德及其附属公司——列为关注公司。


《生物安全法》对中国生物技术创新的未来有什么影响?《生物安全法》将如何影响生物技术行业的市场和投资战略?随着美中在生物技术领域的技术竞争升级,跨国公司应该提前注意哪些?在中国的跨国公司可以采取哪些措施来应对《生物安全法》和美中在生物技术领域的竞争?


4月26日,美商会法律工作组与医疗工作组将邀请行业专家对《生物安全法》进行全面解读,涉及话题为:


  • 全面概述《生物安全法》,包括其范围、禁令和关键定义,同时深入研究该法的背景及其主要目标。
  • 如果该法案获得通过,对生命科学和生物技术公司的潜在影响进行分析。
  • 审查该法案的最新修正案,并评估其潜在影响。
  • 分享对该法案在国会的潜在立法轨迹的看法。


活动详情:

  • 活动地点:美商会
  • 时间和日期:5月9日星期四上午 9:00 - 12:00
  • 语言: 中文
  • 联系方式: 王曦,xwang@amchamchina.org; 杨倩钰, ayang@amchamchina.org


注意事项:

  • 参加会议需要报名注册。报名及退款截止时间为5月8日下午5:00(中国时间)。
  • 请使用贵公司的电子邮件地址进行注册。
  • 不接受现场报名。

Tickets

AmCham Member Ticket
Standard Price RMB 150
AmCham Non-member Ticket
Standard Price RMB 450

Speakers

  • Xin Tao (Partner at Baker & McKenzie LLP)

    Xin Tao

    Partner at Baker & McKenzie LLP

    Tao Xin is a member of Baker McKenzie's North America Steering Committee for Healthcare & Life Sciences, and currently heads our US Food and Drug Law Practice. A former research biochemist, Xin brings a deep understanding of the complex scientific issues that relate to the US FDA's legal and regulatory requirements, enabling him to help clients with all phases of product development, manufacturing, and marketing. As the science and technology continues to evolve, Xin supports our clients to constantly innovate and push the boundaries of what's possible in the world of life science. Xin is a frequent speaker and writer on US FDA legal developments related to emerging technology, and he has been selected to serve on the 2023 Law360 Life Sciences Editorial Advisory Board.

    Based in Washington DC, Xin's practice focuses on empowering global scientific innovation through legal compliance. As a seasoned government regulatory counsel, Xin works closely with companies with novel pharmaceutical, medical device, food, and cosmetic applications that require FDA pre-market approval or clearance and FDA Current Good Manufacturing Practices (cGMP) compliance. Xin has extensive experience advising both emerging and established companies on the launching and promoting innovative products such as cell therapy, software as a medical device (SaMD), cell-cultured meat, and AI-empowered digital health devices. He has represented many life science companies during US government investigations and inspections around the world and helped respond to FDA enforcement actions including Form 483 observations, Warning Letters, and Import Alert. Xin also has a strong track record in FDA product recall matters, and with a deep understanding of the intricacies involved in navigating the complex and interrelated legal and scientific issues, Xin can creatively and effectively represent companies in these bet-the-company cases.

    view more
  • Anne Wang (Chief Operating Officer, Greater China at APCO)

    Anne Wang

    Chief Operating Officer, Greater China at APCO

    Ms. Anne Wang is the Chief Operating Officer for APCO Greater China region. She has over 18 years of rich experience in the healthcare sector to advise multinational corporations on their public affairs and advocacy strategies in the China market.

    Ms. Anne Wang oversees the business operation in the Greater China region for APCO, a global advisory and advocacy firm helping leading corporations, foundations and governments navigate a complex world. Throughout the years, she has been dedicated to fuse the best local experience with a global perspective and has built a diverse and experienced consultant team with a unique culture. In the past 10 years, Ms. Anne Wang led the company’s healthcare practice in the Greater China region and has been providing briefing and counselling on China’s macro-economic and healthcare industrial policies to global and China management teams of multinational companies as well as trade and industrial associations.

    Before joining APCO, Ms. Anne Wang worked as a senior project officer in the Health Human Resources Development Center of China's National Health Commission, where she was responsible for international cooperation, policy research and capacity building programs through coordination with various partners including foreign embassies, multinational companies, international universities, and research institutions.

    Ms. Anne Wang holds a bachelor’s degree in clinical medicine from Tianjin Medical University and completed a master's in psychology program at the University of Essex in U.K.

    view more
  • Hong Zhang (Head of PE at Baker McKenzie FenXun)

    Hong Zhang

    Head of PE at Baker McKenzie FenXun

    Zhang Hong has abundant experience in corporate affairs, especially in the areas of cross-border M&A (including PE and VC) and joint ventures. She focuses on domestic and overseas cross-border M&A and related legal issues including complicated PE and VC investment and financing, the restructuring involved in dismantling or setting up ‘red-chip’ structures, pre-IPO equity financing and employee incentives for various types of corporations, as well as strategic cooperation and joint venture business. She has accumulated extensive experience and unique insight across a wide range of sectors such as TMT, Fintech, healthcare, real estate, financial institutions, High Tech and high-end manufacturing.

    Before joining the Firm, Zhang Hong worked in major Chinese and international lawyer firms. She advised numerous Chinese companies in high-profile overseas M&A and assisted multiple prominent international PE firms’ significant M&A transactions and equity investments in the Greater China and Asia region. Zhang Hong is particularly skilful in advising clients on complicated cross-border transactions and providing input of high commercial value. She has also advised large multinational companies on their M&A and restructuring issues in Greater China and Asia, as well as acting as perennial legal counsel for several large Chinese state-owned enterprises (including government control investment companies). Zhang Hong has been selected as a “Next Generation Lawyer” in both China Corporate and M&A and Private Equity/Venture Capital practices by The Legal 500 Asia Pacific 2018 & 2019. She has also been selected as a “Rising Star” in China Corporate and M&A, “Next Generation Partner” in Private Equity in 2020, as well as a “Next Generation Partner” in Corporate/M&A in Legal 500 Asia Pacific 2023 and 2024.

    view more

Venue

WeWork, Pacific Century Place

Floor 5, Gate 5, Pacific Century Place,
2A Workers' Stadium North Road,
Chaoyang District, Beijing, 100027 北京市朝阳区工体北路甲2号,盈科中心5号门5层。 邮编100027

Beijing, Chaoyang District, China

If you have any questions please contact Xi Wang

Contact Organizer

13681124749

Show on map